Insulin glargine and lixisenatide and Insulin isophane
Determining the interaction of Insulin glargine and lixisenatide and Insulin isophane and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using lixisenatide together with insulin isophane (NPH) can increase the risk of hypoglycemia, or low blood sugar. You may need a dose adjustment or more frequent monitoring of your blood sugar to safely use both medications. Let your doctor know if you experience hypoglycemia during treatment. Symptoms of hypoglycemia include headache, dizziness, drowsiness, nervousness, confusion, tremor, nausea, hunger, weakness, perspiration, palpitation, and rapid heartbeat. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration of a glucagon-like peptide-1 (GLP-1) receptor agonist with insulin may potentiate the risk of hypoglycemia. GLP-1 receptor agonists lower blood glucose by stimulating insulin secretion and lowering glucagon secretion.
MANAGEMENT: When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.
- "Product Information. Ozempic (1 mg dose) (semaglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Adlyxin (lixisenatide)." sanofi-aventis, Bridgewater, NJ.
- "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.
- "Product Information. Victoza (liraglutide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
- "Product Information. Tanzeum (albiglutide)." GlaxoSmithKline, Research Triangle Park, NC.
- "Product Information. Byetta (exenatide)." Amylin Pharmaceuticals Inc, San Diego, CA.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin Glargine and Lixisenatide
Generic Name: insulin isophane
Brand name: Humulin N, HumuLIN N KwikPen, Novolin N, ReliOn/NovoLIN N, Insulin Purified NPH Pork, Iletin II NPH Pork, Iletin NPH, HumuLIN N Pen, NovoLIN N PenFill, NovoLIN N Innolet, Humulin N, Novolin N
Synonyms: Insulin NPH
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide-Insulin isophane and insulin regular
- Insulin glargine and lixisenatide-Insulin lispro
- Insulin glargine and lixisenatide-Insulin Lispro (U-100) Cartridges and Pens
- Insulin glargine and lixisenatide-Insulin Lispro (U-100) Vials
- Insulin glargine and lixisenatide-Insulin Lispro (U-200) Pens
- Insulin glargine and lixisenatide-Insulin lispro and insulin lispro protamine
- Insulin isophane-Insulin glargine and lixisenatide Subcutaneous
- Insulin isophane-Insulin glargine, recombinant Subcutaneous
- Insulin isophane-Insulin glulisine
- Insulin isophane-Insulin Glulisine (Cartridges and Pens)
- Insulin isophane-Insulin Glulisine (Vials)
- Insulin isophane-Insulin glulisine Subcutaneous